Xponentia-backed Medsource Ozone hires EY to explore funding options
Subscribe to enjoy similar stories. Mumbai: Faridabad-based Medsource Ozone Biomedicals, an in-vitro diagnostics instruments and reagents manufacturer, has hired the Big 4 audit firm Ernst & Young as an advisor to explore capital-raising options to fund its expansion, said two people familiar with the matter. “The company may look to raise about ₹300-400 crore, and the promoters may liquidate some stake for the incoming investor," one of the people cited above said.
The company plans to reach the ₹500 crore revenue mark over the next 3-4 years, this person said. “While the exact deal structures are yet to be decided, this is part of the company’s larger plans to operate as a professionally run institution," the second person said. Both people spoke on the condition of anonymity as details are private.
Medsource did not respond to Mint’s emailed queries, while Ernst & Young (EY) declined to comment. If successful, this will be the company’s second external funding round in more than four years. Medsource last raised about ₹35 crore from private equity firm Xponentia Capital Partners in 2021 to launch products and expand its distribution in India and overseas.
The company also outlined plans to consider acquisitions and partnerships in adjacent product segments at the time. Medsource’s expansion plan reflects the potential of India’s growing med-tech market, which EY estimates to more than double from $12 billion in FY24 to $50 billion by 2030, with India’s share in the global market projected to surge from 1.65% to 10%-12% within 25 years. The Indian medical device industry comprises five key segments: electronic equipment (56% share), disposables & consumables (26.5%), in-vitro diagnostics (8.1%), implants (7.1%), and
. Read on livemint.com